Cargando…

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma

Previously, we described VSV-GP, a modified version of the vesicular stomatitis virus, as a non-neurotoxic oncolytic virus that is effective for the treatment of malignant glioblastoma and ovarian cancer. Here, we evaluate the therapeutic efficacy of VSV-GP for malignant melanoma. All of the human,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimpel, Janine, Urbiola, Carles, Koske, Iris, Tober, Reinhard, Banki, Zoltan, Wollmann, Guido, von Laer, Dorothee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869501/ https://www.ncbi.nlm.nih.gov/pubmed/29498639 http://dx.doi.org/10.3390/v10030108

Ejemplares similares

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
por: Dold, Catherine, et al.
Publicado: (2016)

The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer
por: Schreiber, Liesa-Marie, et al.
Publicado: (2019)

The viral vector vaccine VSV-GP boosts immune response upon repeated applications
por: Tober, R, et al.
Publicado: (2012)

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
por: Koske, Iris, et al.
Publicado: (2019)

Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum
por: Pipperger, Lisa, et al.
Publicado: (2019)

The Methyltransferase Region of Vesicular Stomatitis Virus L Polymerase Is a Target Site for Functional Intramolecular Insertion
por: Heilmann, Emmanuel, et al.
Publicado: (2019)

Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants
por: Pipperger, Lisa, et al.
Publicado: (2021)

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP
por: Gautam, Saurabh, et al.
Publicado: (2022)

Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP
por: Vijver, Saskia V., et al.
Publicado: (2023)

RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization
por: Wilmschen, Sarah, et al.
Publicado: (2019)

A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity
por: Das, Krishna, et al.
Publicado: (2021)

Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria
por: Bánki, Zoltán, et al.
Publicado: (2022)

Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
por: Rössler, Annika, et al.
Publicado: (2022)

Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma
por: Krabbe, Teresa, et al.
Publicado: (2021)

Chemogenetic ON and OFF switches for RNA virus replication
por: Heilmann, E., et al.
Publicado: (2021)

Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity
por: Rössler, Annika, et al.
Publicado: (2022)

Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV
por: Yarde, Danielle N., et al.
Publicado: (2013)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Can high COVID-19 vaccination rates in adults help protect unvaccinated children? Evidence from a unique mass vaccination campaign, Schwaz/Austria, March 2021
por: Winner, Hannes, et al.
Publicado: (2022)

Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants
por: Volland, André, et al.
Publicado: (2021)

Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review
por: Moglan, Abdulaziz Molham, et al.
Publicado: (2023)

Construction of VSVΔ51M oncolytic virus expressing human interleukin-12
por: Abdulal, Rwaa H., et al.
Publicado: (2023)

A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Comparison of Four SARS-CoV-2 Neutralization Assays
por: Riepler, Lydia, et al.
Publicado: (2020)

Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
por: Paetzold, Jörg, et al.
Publicado: (2022)

Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers
por: Melzer, Michael Karl, et al.
Publicado: (2018)

Incorporation of CD55 into the Zika Viral Envelope Contributes to Its Stability against Human Complement
por: Malekshahi, Zahra, et al.
Publicado: (2021)

Marked Increase in Avidity of SARS-CoV-2 Antibodies 7–8 Months After Infection Is Not Diminished in Old Age
por: Pichler, Daniel, et al.
Publicado: (2021)

Reduced sensitivity of antibody tests after omicron infection
por: Rössler, Annika, et al.
Publicado: (2023)

Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl
por: Borena, Wegene, et al.
Publicado: (2021)

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial
por: Bánki, Zoltán, et al.
Publicado: (2022)

Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity
por: Ayala Breton, Camilo, et al.
Publicado: (2015)

Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
por: Kottke, Timothy, et al.
Publicado: (2021)

Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
por: Cook, Joselle, et al.
Publicado: (2022)

Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy
por: Marek, Janina, et al.
Publicado: (2023)

Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay
por: Borena, Wegene, et al.
Publicado: (2021)

Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy
por: Muik, Alexander, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0mfj3voc4qaeovoph2gfcks4f9